Corvus Pharmaceuticals (CRVS) Change in Cash (2022 - 2025)
Corvus Pharmaceuticals has reported Change in Cash over the past 4 years, most recently at $1.7 million for Q4 2025.
- Quarterly results put Change in Cash at $1.7 million for Q4 2025, down 57.91% from a year ago — trailing twelve months through Dec 2025 was -$4.2 million (down 7.32% YoY), and the annual figure for FY2025 was -$4.2 million, down 7.32%.
- Change in Cash for Q4 2025 was $1.7 million at Corvus Pharmaceuticals, up from -$11.8 million in the prior quarter.
- Over the last five years, Change in Cash for CRVS hit a ceiling of $12.4 million in Q3 2023 and a floor of -$32.0 million in Q1 2022.
- Median Change in Cash over the past 4 years was -$3.6 million (2023), compared with a mean of -$3.7 million.
- Peak annual rise in Change in Cash hit 469.99% in 2024, while the deepest fall reached 181.63% in 2024.
- Corvus Pharmaceuticals' Change in Cash stood at -$11.4 million in 2022, then surged by 34.51% to -$7.5 million in 2023, then surged by 154.24% to $4.1 million in 2024, then crashed by 57.91% to $1.7 million in 2025.
- The last three reported values for Change in Cash were $1.7 million (Q4 2025), -$11.8 million (Q3 2025), and $9.7 million (Q2 2025) per Business Quant data.